The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Anti-BCMA CAR T-cell therapy in myeloma: updates from ASH 2020
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute, Charlotte, NC, provides an overview of the latest trial updates presented at ASH 2020 for several B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma. He also discusses the promise of off-the-shelf allogeneic CAR T-cell therapies but considers the potential obstacles related to this treatment modality. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
